Corcept Therapeutics Kohustused 2024

Mis teeb Corcept Therapeutics?

Corcept Therapeutics Inc is a biopharmaceutical company specializing in the development of drugs for the treatment of metabolic, hormonal, and cancer-related diseases. The company was founded in 1998 by Dr. Joseph Belanoff, who still serves as the Chief Executive Officer. The history of Corcept Therapeutics is closely linked to the discovery of mifepristone, a drug that acts as an antagonist to cortisol receptors. In 2002, the company acquired the rights to mifepristone from Roussel Uclaf, a subsidiary of Hoechst AG, and developed it into the drug Korlym (mifepristone). Korlym was approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of patients with endogenous Cushing's syndrome, a severe hormone disorder. The core business of Corcept Therapeutics is the research and development of drugs that affect the body's hormonal balance. In addition to Korlym, the company has also brought other innovative drugs to the market aimed at alleviating or even curing the symptoms of hormonal disorders. These drugs include relacorilant, which is currently undergoing Phase III studies for the treatment of patients with Cushing's syndrome. Another division of Corcept Therapeutics is the development of drugs for the treatment of cancer. The company has conducted several clinical trials to test the efficacy of its drug Korlym in treating certain types of cancer, including breast cancer, lung cancer, and prostate cancer. More recently, Corcept Therapeutics has also developed a new drug called Exicure, which focuses on the treatment of liver cancer. Overall, Corcept Therapeutics has built a wide portfolio of products and services targeting patients with different medical needs. The company has also formed partnerships with other companies and research institutes to support its research and development efforts and improve access to its products. The business model of Corcept Therapeutics is based on partnerships with physicians, hospitals, and clinics that utilize its products and services to help patients with metabolic, hormonal, and cancer-related diseases. The company also relies on close collaboration with the FDA and other regulatory agencies to ensure that its drugs meet the highest standards of safety and efficacy. Corcept Therapeutics is headquartered in Menlo Park, California, USA, and currently employs around 250 people. The company has experienced strong growth in recent years, both through the development of new products and the expansion of its business into global markets. In summary, Corcept Therapeutics Inc is a leading biopharmaceutical company specializing in the development of drugs for the treatment of hormone, metabolic, and cancer-related diseases. With its broad portfolio of innovative products and services, the company has made a significant contribution to improving the health and well-being of millions of people worldwide. Corcept Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.